US 9512224
Use of semaphorin-4D binding molecules for treatment of atherosclerosis
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 9512224 (Use of semaphorin-4D binding molecules for treatment of atherosclerosis) held by VACCINEX, INC. expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61P, A61P7/02